logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Fosun Pharma (600196.SH): Lenvatinib Tablets Sirolimus Obtain Drug Registration Approval

date
31/05/2025
Zhixin Finance APP News, Fosun Pharma (600196.SH) announced that its controlling subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. has received approval from the National Medical Products Administration for the market registration application of Lenvatinib Mesylate Tablets (trade name: Fomaiding). The approved indications include treatment for (1) adult patients with Langerhans cell histiocytosis (LCH) and adult patients with tissue cell tumors; (2) children and adolescents aged 2 years and older with symptomatic, inoperable type I neurofibromatosis (NF1) associated with plexiform neurofibromatosis (PN).
Latest
1 m ago
CITIC Securities released a research report pointing out that since May, long-term bond interest rates have been weak and fluctuating. Recently, investors have two main concerns about the bond market: one is the worry that some institutions may have a large number of preventive redemptions of fund holdings, and the other is the concern that banks may actively sell bonds near the end of the quarter in order to realize floating profits in their OCI accounts. Based on data observations, CITIC Securities believes that institutional behavior disruptions are not the main driving factors affecting the recent pricing of the bond market. The fundamental factors driving investor choices and market sentiment still lie in judgments and reflections on macro factors such as funds, tariffs, and fundamentals. The risk of a significant upward adjustment in long-term bond interest rates in the short term is limited, but whether short-term easing can be realized and trigger a downward breakthrough still remains to be seen and will continue to be a key focus for the market.
1 m ago
CITIC Securities: The risk of a substantial increase in long-term interest rates in the short term is limited, but a breakthrough downwards still needs to wait for triggering.
2 m ago
CITIC Securities: Still expects the Federal Reserve to cut interest rates no more than 2 times this year.
2 m ago
CITIC Securities released a research report pointing out that it is expected that the global economic growth will continue to decline in the second half of 2025. Overseas inflation stickiness is gradually fading out of the market's view, and tariffs are becoming a new key variable. Tariff-induced commodity inflation may cause the overall CPI in the United States to rebound in the second half of the year. CITIC Securities still expects the Federal Reserve to cut interest rates less than or equal to 2 times this year, or to cut interest rates again at the September meeting; the European Central Bank may maintain the deposit facility rate at 2% after cutting interest rates by 25 basis points in June; the Bank of Japan may wait for progress in U.S.-Japan tariff negotiations and raise interest rates by 25 basis points in the third quarter. The U.S. tax reduction bill may encounter obstacles in legislation, but the expansion direction is clear, and the path of fiscal expansion in the European Union is also clear. It is recommended to seek trading opportunities for various assets in high volatility in asset allocation.
6 m ago
National Bureau of Statistics: High-tech manufacturing continued to expand in May.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.